Adrenomed Appoints Wolfgang Baiker as CEO

04.01.2021 - German biopharmaceutical company Adrenomed has appointed Wolfgang Baiker as Chief Executive Officer (CEO), effective Jan. 1, 2021.

Baiker has over 30 years of experience in the pharmaceutical and biotechnology industry, and until his recent retirement was President and CEO of Boehringer Ingelheim USA. Previously, he held various roles at Boehringer Ingelheim, including Head of Global Development, Head of Global Manufacturing and Global Quality, as well as Head of the Biopharmaceutical Business Unit.

Currently, Baiker is a Venture Partner with Wellington Partners, chairs the Board of Trustees of the Max Planck Institute of Polymer Research and sits on multiple boards of biopharmaceutical start-up companies. He studied medicine at the Universities of Bochum, Berlin, Ulm, Sheffield and Munich and obtained his Ph.D. from the University of Ulm and an MBA from Pace University in New York.